Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes

This publication has 36 references indexed in Scilit:

• DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury
  American Journal of Physiology-Renal Physiology, 2012
• Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus
  The American Journal of Cardiology, 2012
• Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies
  Pharmacoepidemiology and Drug Safety, 2012
• Comparative effectiveness of incident oral antidiabetic drugs on kidney function
  Kidney International, 2012
• Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
  New England Journal of Medicine, 2011
• Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis
  American Journal of Kidney Diseases, 2010
• Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats
  Journal of Endocrinology, 2008
• Dipeptidyl peptidase IV inhibition downregulates Na⁺-H⁺exchanger NHE3 in rat renal proximal tubule
  American Journal of Physiology-Renal Physiology, 2008
• Efficacy and Safety of Incretin Therapy in Type 2 Diabetes
  JAMA, 2007
• Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
  Diabetes Care, 2006